Striatal dopaminergic denervation and gait in healthy adults

Experimental Brain Research

Volumn 185, Issue 3, 2008, Pages 391-398

  Cham, R ^a   Studenski, S A ^b,c   Perera, S ^b,d   Bohnen, N I ^e,f  

^a University of Pittsburgh   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Pittsburgh VA GRECC   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f VA Ann Arbor Healthcare System   (United States)

Author keywords

Aging; Dopamine; Gait; Parkinson's Ddisease

Indexed keywords

2 BETA CARBOMETHOXY 3' (4 FLUOROPHENYL)TROPANE; DOPAMINE TRANSPORTER; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; CORPUS STRIATUM; DENERVATION; DOPAMINERGIC NERVE CELL; FEMALE; GAIT; HUMAN; HUMAN EXPERIMENT; MALE; MODEL; NERVE CELL NECROSIS; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WALKING; WALKING SPEED;

ADULT; AGED; AGED, 80 AND OVER; AGING; CORPUS STRIATUM; DENERVATION; DOPAMINE; FEMALE; GAIT; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; WALKING;

EID: 39149134325     PISSN: 00144819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00221-007-1161-3     Document Type: Article

References (34)

1. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL (1997) Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 12:33-38
2. Azulay JP, Van Den Brand C, Mestre D, Blin O, Sangla I, Pouget J, Serratrice G (1996) Automatic motion analysis of gait in patients with Parkinson disease: effects of levodopa and visual stimulations. Rev Neurol 152:128-134
3. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334:71-76
4. Blin O, Ferrandez AM, Pailhous J, Serratrice G (1991) Dopa-sensitive and dopa-resistant gait parameters in Parkinson's disease. J Neurol Sci 103:51-454
5. Bloem BR, van Vugt JP, Beckley DJ (2001) Postural instability and falls in Parkinson's disease. Adv Neurol 87:209-223
6. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, Frey KA (2006) Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 26:1198-1212
7. Bowes SG, Clark PK, Leeman AL, O'Neill CJ, Weller C, Nicholson PW, Deshmukh AA, Dobbs SM, Dobbs RJ (1990) Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy. Br J Clin Pharm 30:13-24
8. Cham R, Perera S, Studenski SA, Bohnen NI (2007) Striatal dopamine denervation and sensory integration for balance in middle-aged and older adults. Gait Posture 26(4):516-525
9. Fahn S, Elton R (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden C, Calne D, Goldstein M (eds) Recent developments in Parkinson's disease. Macmillan Healthcare Information, Florham Park, pp 153-164
10. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114:2283-2301
11. Ferrandez AM, Blin O (1991) A comparison between the effect of intentional modulations and the action of l-dopa on gait in Parkinson's disease. Behav Brain Res 45:177-183
12. Fleischman DA, Wilson RS, Schneider JA, Bienias JL, Bennett DA (2007) Parkinsonian signs and functional disability in old age. Exp Aging Res 33:59-76
13. Hausdorff JM, Schaafsma JD, Balash Y, Bartels AL, Gurevich T, Giladi N (2003) Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait. Exp Brain Res 149:187-194
14. Hornykiewicz O (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 18:925-964
15. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096-1112
16. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 11:735-744
17. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158
18. Lee MS, Rinne JO, Marsden CD (2000) The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J 41:167-184
19. Matsumoto N, Hanakawa T, Maki S, Graybiel AM, Kimura M (1999) Role of nigrostriatal dopamine system in learning to perform sequential motor tasks in a predictive manner. J Neurophysiol 82:978-998
20. 11C]beta-CFT. Nucl Med Biol 22:965-979
21. 11C]methyl triflate. Nucl Med Biol 22:235-239
22. O'Sullivan JD, Said CM, Dillon LC, Hoffman M, Hughes AJ (1998) Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function. Movement Disorders 13:900-906
23. Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Tanaka K (2001) Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease. Brain 124:784-792
24. Pahapill PA, Lozano AM (2000) The pedunculopontine nucleus and Parkinson's disease. Brain 123(Pt 9):1767-1783
25. Schaafsma JD, Giladi N, Balash Y, Bartels AL, Gurevich T, Hausdorff JM (2003) Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa. J Neurol Sci 212:47-53
26. Shan DE, Lee SJ, Chao LY, Yeh SI (2001) Gait analysis in advanced Parkinson's disease-effect of levodopa and tolcapone. Can J Neurol Sci 28:70-75
27. Visser JE, Bloem BR (2005) Role of the basal ganglia in balance control. Neural Plast 12:161-174
28. Volkow ND, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS, Hitzemann R, Smith G, Logan J (1998a) Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 155:344-349
29. Volkow ND, Wang GJ, Fowler JS, Ding YS, Gur RC, Gatley J, Logan J, Moberg PJ, Hitzemann R, Smith G, Pappas N (1998b) Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 44:143-147
30. Volkow ND, Logan J, Fowler JS, Wang GJ, Gur RC, Wong C, Felder C, Gatley SJ, Ding YS, Hitzemann R, Pappas N (2000) Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry 157:75-80
31. Wilson RS, Schneider JA, Beckett LA, Evans DA, Bennett DA (2002) Progression of gait disorder and rigidity and risk of death in older persons. Neurology 58:1815-1819
32. Wiseman MB, Nichols TE, Woods RP, Sweeney JA, Mintun MA (1995) Stereotaxic techniques comparing foci intensity and location of activation areas in the brain as obtained using positron emission tomography (PET). J Nucl Med 36 (suppl):93P
33. Woods RP, Mazziotta JC, Cherry SR (1993) MRI-PET registration with automated algorithm. J Comput Assis Tomogr 17:536-546
34. Wu Y, Carson RE (2002) Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab 22:1440-1452